1. GSK aims to make 1B doses of vaccine booster for multiple COVID-19 partners — Protalix and Chiesi get close to potential Fabry disease treatment approval — AstraZeneca locks up COVID-19 vaccine supply with Oxford BioMedica deal — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice


Discussion in 'Jazz Pharmaceuticals' started by anonymous, Dec 4, 2018 at 2:56 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    What is the short and long-term potential for Solriamfetol with current/future treatment options? Other indications?

    There is not a lot of info out there except from results of phase 3 studies and a few comments from lead investigators. Does not seem to be much excitement from Jazz or the market about new entrant to market if approved.